Information Provided By:
Fly News Breaks for March 20, 2017
Mar 20, 2017 | 08:10 EDT
Roth Capital analyst Mark Breidenbach raised his price target for Kite Pharma to $93 from $83 as he believes the company will be ready for launch this year after discussions with management and touring its new El Segundo manufacturing facility. The analyst says autologous CAR-T manufacturing is relatively simple compared to that of other biologics, and he is confident the facility is capable of meeting the U.S. demand in DLBCL. He reiterates a Buy rating on the shares.
News For KITE From the Last 2 Days
Oct 16, 2017 | 15:30 EDT
25th Anniversary Congress of the ESGCT will be held in Berlin, Germany on October 17-20.
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.